- Home
- PGZ vs INCR Comparison
PGZ vs INCR Comparison
Compare PGZ & INCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PGZ | INCR |
|---|---|---|
| Founded | 2012 | 1994 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 69.4M | 68.0M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | PGZ | INCR |
|---|---|---|
| Price | $9.89 | $1.44 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 23.0K | ★ 25.4K |
| Earning Date | 01-01-0001 | 10-08-2025 |
| Dividend Yield | ★ 12.26% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $72,158,312.00 |
| Revenue This Year | N/A | $69.54 |
| Revenue Next Year | N/A | $41.75 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.46 | $1.22 |
| 52 Week High | $10.59 | $1.79 |
Technical Indicators
Market Signals| Indicator | PGZ | INCR |
|---|---|---|
| Relative Strength Index (RSI) | 29.64 | 63.31 |
| Support Level | $9.87 | $1.35 |
| Resistance Level | $10.09 | $1.45 |
| Average True Range (ATR) | 0.07 | 0.06 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 5.56 | 90.95 |
Price Performance
Historical ComparisonAbout PGZ Principal Real Estate Income Fund of Beneficial Interest
Principal Real Estate Income Fund is a non-diversified, closed-end management investment company. Its investment objective is to provide high current income with capital appreciation by investing in commercial real estate-related securities. The company does its investments in USA, Australia, Japan, France, Great Britain, Canada, Hong Kong, Germany, Singapore, South Korea, British Virgin Islands and more.
About INCR Intercure Ltd.
Intercure Ltd is engaged in the research, cultivation, production, and distribution of pharma-grade cannabis-based products. Its products are available in dried inflorescences or liquid oil form, and are marketed through various brands, including Pharmo Cann, Humboldt, Indoor, Space Labs, Canndoc Utopia, Binske, Canndoc Stars, and others. The company has two operating segments, namely Investments in portfolio companies in the biomed sector and Investments in the medical cannabis sector. A majority of its revenue is generated from the Cannabis segment.